NASDAQ:ORMP Oramed Pharmaceuticals - ORMP Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.16 -0.06 (-2.70%) (As of 03/22/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.13▼$2.2450-Day Range$1.93▼$2.5452-Week Range$1.81▼$13.73Volume629,846 shsAverage Volume1.99 million shsMarket Capitalization$85.92 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Oramed Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside779.6% Upside$19.00 Price TargetShort InterestHealthy2.66% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.86Based on 8 Articles This WeekInsider TradingAcquiring Shares$293,240 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector593rd out of 986 stocksPharmaceutical Preparations Industry287th out of 477 stocks 3.0 Analyst's Opinion Consensus RatingOramed Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.00, Oramed Pharmaceuticals has a forecasted upside of 779.6% from its current price of $2.16.Amount of Analyst CoverageOramed Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.66% of the outstanding shares of Oramed Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverOramed Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oramed Pharmaceuticals has recently increased by 8.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOramed Pharmaceuticals does not currently pay a dividend.Dividend GrowthOramed Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ORMP. Previous Next 2.7 News and Social Media Coverage News SentimentOramed Pharmaceuticals has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Oramed Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for ORMP on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Oramed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oramed Pharmaceuticals insiders have bought 75.35% more of their company's stock than they have sold. Specifically, they have bought $293,240.00 in company stock and sold $167,229.00 in company stock.Percentage Held by InsidersOnly 6.90% of the stock of Oramed Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 10.08% of the stock of Oramed Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Oramed Pharmaceuticals is -2.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oramed Pharmaceuticals is -2.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOramed Pharmaceuticals has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Oramed Pharmaceuticals (NASDAQ:ORMP) StockOramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.Read More Receive ORMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ORMP Stock News HeadlinesMarch 18, 2023 | americanbankingnews.comNadav Kidron Buys 26,000 Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) StockMarch 18, 2023 | americanbankingnews.comNadav Kidron Acquires 100,000 Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) StockMarch 22, 2023 | Investing Daily (Ad)How This Trader Banked A 97% Win RateDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. March 16, 2023 | benzinga.comOramed Pharmaceuticals Chief Scientific Officer Sold $200K In Company StockMarch 16, 2023 | benzinga.comDirector of Oramed Pharmaceuticals Makes $141K BuyMarch 15, 2023 | americanbankingnews.comResearch Analysts Set Expectations for Oramed Pharmaceuticals Inc.'s Q1 2023 Earnings (NASDAQ:ORMP)March 13, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Oramed Pharm (ORMP)February 16, 2023 | finance.yahoo.comOramed Pharmaceuticals Inc. (ORMP.TA)March 22, 2023 | Investing Daily (Ad)How This Trader Banked A 97% Win RateDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. February 9, 2023 | finance.yahoo.comOramed Pharmaceuticals Issues Shareholder UpdateJanuary 25, 2023 | finance.yahoo.comORMP: ORA-D-013-1 Failed To Meet Endpoints; Ending T2D Oral Insulin EffortsJanuary 12, 2023 | seekingalpha.comHot Stocks: CTSH rises on guidance; LOGI slumps; CAT hits 52-week high; ORMP plunges 76%January 12, 2023 | marketwatch.comOramed Pharmaceuticals Shares Crumble as Diabetes Drug Fails >ORMPJanuary 12, 2023 | finance.yahoo.comWhy Oramed Pharmaceuticals Stock Is Crashing TodayJanuary 12, 2023 | finance.yahoo.comOramed Pharmaceuticals Stock Plummets After Insulin Test ResultsJanuary 12, 2023 | seekingalpha.comOramed stock slumps ~70% as diabetes drug fails phase 3 studyJanuary 12, 2023 | marketwatch.comOramed Pharmaceuticals Shares Plummet Premarket on Study Failure >ORMPJanuary 12, 2023 | finance.yahoo.comOramed Pharma Shares Sink After Diabetes Candidate Fails In Phase 3 StudyJanuary 12, 2023 | finance.yahoo.comOramed’s oral insulin pill fails; stock is down 72%January 12, 2023 | markets.businessinsider.comOramed To Stop Oral Insulin Clinical Activities For Type 2 Diabetes Following Disappointing ResultsJanuary 8, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn SituationDecember 22, 2022 | msn.comLooking Into Oramed Pharmaceuticals's Return On Capital EmployedNovember 21, 2022 | finance.yahoo.comORMP: Data from NASH Phase 2 Study – Positive TakeawaysNovember 18, 2022 | finance.yahoo.comOramed Pharma Shares Fall After Additional Data From Oral Insulin StudyNovember 17, 2022 | finance.yahoo.comOramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASHNovember 16, 2022 | finance.yahoo.comOramed Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 14, 2022 | finance.yahoo.comOramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South KoreaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ORMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ORMP Company Calendar Last Earnings1/10/2022Today3/22/2023Next Earnings (Estimated)5/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ORMP CUSIPN/A CIK1176309 Webwww.oramed.com Phone(844) 967-2633Fax972-2566-0004Employees12Year FoundedN/APrice Target and Rating Average Stock Price Forecast$19.00 High Stock Price Forecast$35.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+779.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,560,000.00 Net Margins-1,353.35% Pretax Margin-1,393.42% Return on Equity-23.62% Return on Assets-22.15% Debt Debt-to-Equity RatioN/A Current Ratio27.34 Quick Ratio27.34 Sales & Book Value Annual Sales$2.70 million Price / Sales31.82 Cash FlowN/A Price / Cash FlowN/A Book Value$3.86 per share Price / Book0.56Miscellaneous Outstanding Shares39,780,000Free Float37,039,000Market Cap$85.92 million OptionableOptionable Beta1.83 Key ExecutivesNadav KidronPresident, Chief Executive Officer & DirectorJoshua HexterChief Operating & Business OfficerMiriam KidronDirector & Chief Scientific OfficerMichael RabinowitzChief Commercial OfficerEstee YaariInvestor Relations ContactKey CompetitorsEliem TherapeuticsNASDAQ:ELYMSol-Gel TechnologiesNASDAQ:SLGLFortress BiotechNASDAQ:FBIOInflaRxNASDAQ:IFRXReviva PharmaceuticalsNASDAQ:RVPHView All CompetitorsInsiders & InstitutionsNadav KidronBought 26,000 shares on 3/16/2023Total: $53,040.00 ($2.04/share)Nadav KidronBought 100,000 shares on 3/14/2023Total: $201,000.00 ($2.01/share)Yadin RozovBought 20,000 shares on 3/13/2023Total: $39,200.00 ($1.96/share)Altshuler Shaham LtdBought 12,847 shares on 2/16/2023Ownership: 0.033%Millennium Management LLCSold 12,828 shares on 2/15/2023Ownership: 1.253%View All Insider TransactionsView All Institutional Transactions ORMP Stock - Frequently Asked Questions Should I buy or sell Oramed Pharmaceuticals stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ORMP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORMP, but not buy additional shares or sell existing shares. View ORMP analyst ratings or view top-rated stocks. What is Oramed Pharmaceuticals' stock price forecast for 2023? 3 brokers have issued 1-year target prices for Oramed Pharmaceuticals' stock. Their ORMP share price forecasts range from $3.00 to $35.00. On average, they expect the company's stock price to reach $19.00 in the next year. This suggests a possible upside of 779.6% from the stock's current price. View analysts price targets for ORMP or view top-rated stocks among Wall Street analysts. How have ORMP shares performed in 2023? Oramed Pharmaceuticals' stock was trading at $12.03 at the beginning of 2023. Since then, ORMP shares have decreased by 82.0% and is now trading at $2.16. View the best growth stocks for 2023 here. When is Oramed Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our ORMP earnings forecast. How were Oramed Pharmaceuticals' earnings last quarter? Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced its quarterly earnings results on Monday, January, 10th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.06. The biotechnology company earned $0.67 million during the quarter, compared to the consensus estimate of $0.70 million. Oramed Pharmaceuticals had a negative net margin of 1,353.35% and a negative trailing twelve-month return on equity of 23.62%. What ETFs hold Oramed Pharmaceuticals' stock? ETFs with the largest weight of Oramed Pharmaceuticals (NASDAQ:ORMP) stock in their portfolio include BlueStar Israel Technology ETF (ITEQ).Invesco Nasdaq Future Gen 200 ETF (QQQS). What other stocks do shareholders of Oramed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN). What is Oramed Pharmaceuticals' stock symbol? Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP." Who are Oramed Pharmaceuticals' major shareholders? Oramed Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Millennium Management LLC (1.25%), JPMorgan Chase & Co. (1.03%), Lindbrook Capital LLC (0.98%), Morgan Stanley (0.81%), Susquehanna International Group LLP (0.00%) and Citigroup Inc. (0.17%). Insiders that own company stock include Kevin Rakin, Michael Rabinowitz, Nadav Kidron and Yadin Rozov. View institutional ownership trends. How do I buy shares of Oramed Pharmaceuticals? Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Oramed Pharmaceuticals' stock price today? One share of ORMP stock can currently be purchased for approximately $2.16. How much money does Oramed Pharmaceuticals make? Oramed Pharmaceuticals (NASDAQ:ORMP) has a market capitalization of $85.92 million and generates $2.70 million in revenue each year. The biotechnology company earns $-36,560,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. How can I contact Oramed Pharmaceuticals? Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The official website for the company is www.oramed.com. The biotechnology company can be reached via phone at (844) 967-2633, via email at ir@oramed.com, or via fax at 972-2566-0004. This page (NASDAQ:ORMP) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.